Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J. Clin. Oncol. 26, 5544–5552 (2008).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback